乌梅丸联合三联疗法治疗慢性萎缩性胃炎临床研究  

Clinical observation of Wumeiwan combined with triple therapy for treatment of chronic atrophic gastritis

作　　者：马银平 靳秀芳 徐凤超 陈明岩[3] Ma Yinping;Jin Xiufang;Xu Fengchao;Chen Mingyan(Department of Pharmacy,Pinggu Hospital of Beijing Chinese Medicine Hospital,Beijing 101200,China)

机构地区：[1]北京中医医院平谷医院药剂科,101200 [2]吉林大学第一医院实验室,长春130021 [3]吉林大学第四医院普通外科,长春130021

出　　处：《国际中医中药杂志》2018年第8期702-705,共4页International Journal of Traditional Chinese Medicine

摘　　要：目的 评价乌梅丸联合三联疗法治疗慢性萎缩性胃炎（chronic atrophic gastritis, CAG）的疗效。方法 将符合入选标准的113例CAG患者按随机数字表法分为对照组56例、治疗组57例。对照组给予三联疗法（奥美拉唑＋阿莫西林＋克拉霉素）治疗，治疗组在对照组治疗的基础上加用乌梅丸。2组均连续治疗3个月。采用ELISA法检测血清TNF-a、IL-6及IL-8水平，以流式细胞仪检测外周血CD3＋、CD4＋、CD8＋水平，采用14C呼气试验观察患者H.pylori阴转情况，评价临床疗效，记录不良反应。结果 治疗组总有效率为94.7%（54/57），对照组为82.1%（46/56），2组比较差异有统计学意义（χ2＝4.401，P＝0.036）。治疗组的H.pylori转阴率为88.2%（45/51），对照组为48.0%（24/50），2组比较差异有统计学意义（χ2＝18.883，P＜0.001）。治疗后，治疗组血清TNF-a[（1.43±0.17）mg/L比（1.97±0.22）mg/L，t＝14.615]、IL-6[（30.79±3.65）ng/L比（41.13±4.10）ng/L，t＝14.166]及IL-8[（7.52±1.32）ng/L比（9.60±1.77）ng/L，t＝7.090]水平均低于对照组（P＜0.05）。治疗后，治疗组外周血CD3＋[（75.12±16.44）%比（67.33±14.37）%，t＝2.680]、CD4＋[（39.02±11.41）%比（33.49±10.61）%，t＝2.667]水平及CD4＋/CD8＋[（1.58±0.35）比（1.19±0.32），t＝6.179]均高于对照组，CD8＋[（24.75±9.69）%比（28.12±11.29）%，t＝1.704]水平低于对照组（P＜0.05）。2组治疗过程中不良反应发生率比较，差异无统计学意义（χ2＝0.134，P＝0.714）。结论 乌梅丸联合三联疗法有较强的抗炎作用，可增强CAG患者的免疫功能，提高临床疗效。Objective To explore clinical efficacy and safety of Wumeiwan combined with triple therapy for treatment of chronic atrophic gastritis （CAG）. Methods According to the random indicator method, 113 patients with CAG were divided into control group （n=56） and treatment group （n=57）. Patients of control group were treated with triple therapy, while treatment groupwere treated Wumeiwan combined with triple therapy. The two groups were treated for 3 months. Clinical effect was evaluated after treatment. The helicobacter pylori （Hp） conversion to negative of the two groups was compared and recorded. The Hp overcast conditions of the two groups were compared. The serum TNF-α, IL-6, IL-8 and peripheral blood CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ of the two groups before and after treatment were compared. The adverse reactions of the two groups during the treatment were compared. Results Total effective rate of treatment group was 94.7% （54/57）, which was significantly higher than the control group 82.14% （46/56）, and the difference was statistically significant （χ2=4.401, P=0.036）. Hp overcast rate of treatment group was 88.2% （45/51）, which was significantly higher than the control group 48.0%（24/50）, and the difference was statistically significant （χ2=18.883, P=0.000）. After treatment, the serum TNF-α （1.43 ± 0.17 mg/L vs. 1.97 ± 0.22 mg/L, t=14.615）, IL-6 （30.79 ± 3.65 ng/L vs. 41.13 ± 4.10 ng/L, t=14.166）, IL-8 （7.52 ± 1.32 ng/L vs. 9.60 ± 1.77 ng/L, t=7.090） in the treatment group were lower than those in the control group （P〈0.05）. After treatment, the peripheral blood CD3＋ （75.12% ± 16.44% vs. 67.33% ± 14.37%, t=2.680）, CD4＋ （39.02% ± 11.41% vs. 33.49% ± 10.61%, t=2.667）, CD4＋/CD8＋ （1.58 ± 0.35 vs. 1.19 ± 0.32, t=6.179） in the treatment group were higher than those in the control group （P〈0.05）, the peripheral blood CD8＋ （24.75% ± 9.69% vs. 28.12% ± 11.29%, t=1.704） in the treatment group were higher than th

关 键 词：胃炎 萎缩性 乌梅丸 二三联疗法 疗效 安全性 

分 类 号：R573.32[医药卫生—消化系统]